Spring Discovery, a Palo Alto, CA-based machine learning-based drug discovery platform provider, raised $4.25m in seed funding.
Backers included General Catalyst, First Round, Sam Altman, Longevity Fund, Sea Lane Ventures, Joe Betts-Lacroix, Greg Brockman, etc.
The company intends to use the funds to continue to expand its operations.
Led by Ben Kamens, Founder and CEO, Spring Discovery is accelerating the discovery of therapies for aging and its related diseases with a machine learning-based drug discovery platform, which applies a novel computational approach.
FinSMEs
26/02/2018